Kumari, Romika
Majumder, Muntasir Mamun
Lievonen, Juha
Silvennoinen, Raija
Anttila, Pekka
Nupponen, Nina N.
Lehmann, Fredrik
Heckman, Caroline A. http://orcid.org/0000-0002-4324-8706
Article History
Received: 14 July 2020
Revised: 4 December 2020
Accepted: 11 December 2020
First Online: 3 February 2021
Ethics approval and consent to participate
: The procedures in this study were approved by an ethical committee of the Helsinki University Hospital Comprehensive Cancer Center (study permit 303/13/03/01/2011) and performed in accordance with the Helsinki Declaration of 1975, as revised in 2008. All patients provided their written informed consent.
: Not applicable.
: All data generated or analysed during this study are included in this article (and its supplementary information files).
: All authors met the criteria set forth by the International Committee of Medical Journal Editors and hence adequately contributed to the manuscript development. J.L. has received personal fees from Amgen, Bristol–Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Roche and Takeda. R.S. has received research funding and personal fees from Amgen, Bristol–Myers Squibb, Celgene and Takeda, and personal fees from Sanofi. N.N.N. is a consultant for Oncopeptides AB. F.L. is an employee of Oncopeptides AB. C.A.H. has received research funding from Celgene, Novartis, Oncopeptides AB, Orion Pharma, Pfizer and the IMI2 consortium project HARMONY. P.A. has received personal fees from Amgen, Bayer, Bristol–Meyers–Squibb, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda. R.K. and M.M.M. have nothing to disclose.
: This work has been supported by funding from Oncopeptides, the iCAN Digital Precision Cancer Medicine Flagship (Academy of Finland grant 1320185), Cancer Society of Finland, and Sigrid Jusélius Foundation. Open Access funding provided by University of Helsinki including Helsinki University Central Hospital.